Aurora’s hostile takeover bid for CanniMed goes before provincial regulators

An acrimonious takeover battle between two Canadian marijuana companies was in the regulatory spotlight Wednesday at a joint hearing involving the Saskatchewan and Ontario securities commissions.

Lawyers for both provincial regulators argued that Aurora Cannabis‘ request to lessen the consideration period for its all-stock offer be rejected but that CanniMed Therapeutics shareholders’ rights plan to push back against its suitor be removed.


READ MORE:
Aurora filing dissident circular against CanniMed’s acquisition of Newstrike

Kate McGrann, a lawyer representing staff at both the Ontario Securities Commission and the Financial and Consumer Affairs Authority of Saskatchewan, also told commissioners at the joint hearing that Aurora (TSX:ACB) should be able to buy up to five per cent of CanniMed’s outstanding shares on the open market.

Wednesday’s hearing in Toronto kicking off the joint proceedings comes roughly one month after Aurora launched an all-stock, unsolicited bid to acquire Saskatoon-based CanniMed, one of the first licensed marijuana producers in Canada, after both companies called on regulators to intervene.

CanniMed has said that Aurora’s offer is inferior to its own proposed acquisition of the Tragically Hip-backed Newstrike Resources (TSXV:HIP), and launched a shareholders’ rights plan to push back.


READ MORE:
CanniMed seeks regulatory action against hostile takeover bid by Aurora

CanniMed has alleged that Edmonton-based Aurora worked jointly with some of its shareholders and Aurora has disputed this, while launching a dissident circular in a bid to thwart the Newstrike acquisition.

Source link

Content Source

Buds
Buds
This is the Buds2Go Staff Account. We work really hard to provide information and news about marijuana legalization, product information and promotional events going on across Canada. We are fanatics and experts on strains and utilizing medical cannabis for the treatment of common ailments.

Leave a Reply